SCHOTT Pharma AG & Co. KGaA stock
1SXP.FFSXHealthcareISIN DE000A3ENQ51WKN A3ENQ5
70Score 70 out of 100, Strong
Price and trend
59 / 100
Price history
+15% in one yearThe chart shows daily closes over 3 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 15% above it.
Since July 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Sharply down: the price has fallen very quickly lately (RSI 25).
The price is 17% below its 52-week high. Largest decline in 3 years: 69% (March 2024 to March 2026).
Chart figures for advanced users
- SMA 50$26.62
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$20.95
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)25
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDbelow the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$14.36
- The lowest closing price of the last twelve months.
- Resistance$28.92
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- SCHOTT Pharma AG & Co. KGaA belongs to the Medical (Instruments & Supplies) industry (Germany) and, with a market value of $3.63B, is number 28 of 44 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $1.09B (up 3% year on year) and earnings of $162.29M (down 2.2%).
- For fiscal 2026, analysts expect on average revenue of $1.15B (up 5.4%) and adjusted earnings per share of $1.09 (up 1.2%).
Show more
- MEQIRI Score 70 out of 100 (Strong): rank 119 of 702 in Healthcare, median 53.
- The P/E is 23.8 (Medical (Instruments & Supplies) median 34.6, own median of recent years 31).
- Our model puts fair value at $36.93, with the price 35% below it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Below fair valuePrice 35% below the fair value of $36.93.Valuation 70
- Modestly valuedP/E 23.8, Medical (Instruments & Supplies) median 34.6, own median 31.Valuation 70
- Earnings per share growingUp 13.7% a year since 2020.Growth 75
Weaknesses
None of our weakness checks flags anything. Crash risk is measured separately.
Its standout strengths are stability and growth.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 69 to 70.
Fundamentals are strong, with stable profits.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk medium
How well MEQIRI warnsIn the middle among smaller stocks.
From 2016 to 2025, 20 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What drives the risk
- high price swings
Valuation
Valuation signal
Significantly undervaluedIn our model the price counts as cheap below $28.41 and expensive above $52.76 (uncertainty medium, based on the price swings of the past year).
The two parts of the fair value come to $38.85 (cash-flow model) and $35.01 (industry comparison), and the gap between them shows how uncertain the estimate is. The price is below both.
Calculated with a cost of equity of 7.1%. At 8.1% the fair value would be $33.17, at 6.1% it would be $42.62.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (34.6).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Jun 2026, revenue rose 4.3% on the twelve months before. Revenue has grown solidly since 2020, at about 11% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 34%, operating 18%, net 15%.
Debt & balance sheet
Fiscal 2025The balance sheet is solid, with low debt and comfortable interest coverage.
Earnings
- Next earnings
- 10 Dec 2026in 27 days
- Last reported
- 12 Aug 2026EPS reported $0.28 (expected $0.29)below expectations
Analyst estimates
Earnings estimates have barely changed since 27 Oct 2026.
- Earnings per share
- $1.21+0.1%
- Revenue
- $1.23B0.0%
- Earnings per share
- $1.37−0.2%
- Revenue
- $1.31B0.0%
MEQIRI has stored the estimates since 27 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
What happened at SCHOTT Pharma AG & Co. KGaA
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 70
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Instruments & Supplies)
The next larger and next smaller companies by market value
- Envista HoldingsNVST $3.95B71
- Stevanato GroupSTVN $3.92B49
- Tecan GroupTECN.SW $3.9B52
- Pulse BiosciencesPLSE $3.84B46
- Carl Zeiss MeditecAFX.DE $3.34B64
- AtriCureATRC $2.85B51
- AddLifeALIF-B.ST $2.14B58
- Bonesupport HoldingBONEX.ST $2.07B72
ETFs that hold SCHOTT Pharma AG & Co. KGaA
Held by 19 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| Amundi SDAX UCITS ETF DistC005 | 2.03% | 0.70% | €158.8M |
| Amundi MSCI EMU Small Cap ESG Broad Transition UCITS ETF DISTLGWU | 0.38% | 0.40% | €580.62M |
| WisdomTree Eurozone Quality Dividend Growth UCITS ETF EUR AccWTIM | 0.29% | 0.29% | €49.19M |
Show 5 more
| UBS MSCI EMU Small Cap UCITS ETF EUR disUEFD | 0.17% | 0.28% | €630.46M |
| Amundi F.A.Z. 100 UCITS ETFC006 | 0.13% | 0.15% | €104.39M |
| Amundi MSCI Europe Small Cap ESG Broad Transition UCITS ETF DistX026 | 0.12% | 0.23% | €321.86M |
| Xtrackers MSCI Europe Small Cap UCITS ETF 1CXXSC | 0.07% | 0.30% | €3.45B |
| Vanguard Germany All Cap UCITS ETF (EUR) DistributingVGER | 0.05% | 0.07% | €255.26M |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 30 Sep 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = €0.9024)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong since 13 Nov 2026, previously Neutral
- Valuation signal Undervalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.